ArticleScientific reports2026
Enhanced immunogenicity of the rabies virus glycoprotein fused to a dendritic cell-targeting peptide.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dendritic cell-targeting peptide (DCP) trimer sequence has previously shown to enhance specific IgG induction. This study aims to investigate the expression of rabies virus glycoprotein (RVG) in eukaryotic cells through cloning in the pCDNA3.1 + vector, alongside the fusion of a DCP. The DCP trimer sequence was fused to the C-terminal of the RVG to improve the immune response. The construct was designed to include a His-tag for protein purification and an enterokinase (EK) cleavage site for separation of the tag from the recombinant protein. The RVG gene was amplified from the rabies virus genome via RT-PCR, and cloning was performed using BamHI and EcoRI restriction enzymes. The recombinant plasmid (RVG- pCDNA3.1+) was transfected into BHK-21 cells using lipofection, and the expression of the recombinant protein was confirmed through SDS-PAGE and western blotting using anti-His antibodies. The His-tagged recombinant protein was purified using Ni-NTA resin. Immunogenicity of the recombinant protein was investigated through mouse inoculation and analysis of the serum samples using RFFIT and ELISA methods. The results indicated successful cloning and expression of the RVG-DCP fusion protein in eukaryotic cells, with potential applications in rabies vaccine development. The results suggests a novel method for enhancing the immunogenicity of viral glycoproteins through the use of dendritic cell-targeting peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.